ABSTRACT

Since the pandemic began (COVID19), India has confirmed more than 38 million cases and over 487,719 deaths. The country has recorded the second-highest number of Covid-19 infections in the world after the United States. India launched first home-made vaccine "Covaxin" in January, 2021 to eradicate the corona virus.Bharat Biotech International Limited in collaboration with Indian Council of Medical Research (ICMR) has developed an inactivated whole virion COVID-19 vaccine, COVAXIN. The COVAXIN has been evaluated for its safety, reactogenicity and immunogenicity in phase 1 and 2 clinical trials and the trial reports were submitted to the Central Drugs Standard Control Organization (CDSCO) India. The double-dose vaccine showed significantly higher neutralizing antibody responses in Phase II than in Phase I due to the difference in dosing regimens that changed to a 4-week apart injection schedule from a 2-week course. by December 31, 89.4% of adults had received their first dose and 64.2% had been fully vaccinated The purpose of the paper is to aware the whole community regarding the India’s first developed vaccine COVAXIN, its safety and efficacy, adverse effects and minimum complications like others vaccine. This is one of the promising weapons to fight against unknown COVID19, the silent killer. As per Government circular the price of Covid vaccines (COVAXIN) at private hospitals at Rs 1410 per dose. The reasonable cost of the vaccine, the common people can easily take the vaccine to protect from corona virus. So, India’s developed vaccine COVAXINtakes a role to eradicate the coronavirus in the near future and save millions of people’s lives against COVID19. Keywords: Covid-19, Covaxin, India Vaccine, Virus, Bharat Biotech, Virology
Publication date: 25/01/2022

https://ijbpas.com/pdf/2022/January/MS_IJBPAS_2022_JAN_SPCL_2_2030.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2022/11.1.2030